Dengue Virus IgM µ-capture ELISA Kit (Human)
Cat# OKNA00132
Size : 96Wells
Brand : Aviva Systems Biology
Datasheets/Manuals | Click here to download product manual. As variation between lots may occur, always reference the lot-specific manual received with each kit. |
---|
Predicted Species Reactivity | Human | ||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ELISA Kit Detection Method | Colorimetric, OD450 nm | ||||||||||||||||||||||||||||||||||
ELISA Kit Duration | ~3 Hours | ||||||||||||||||||||||||||||||||||
ELISA Kit Principle | Aviva Systems Biology Dengue Virus IgM u-capture ELISA Kit (Human) (OKNX00132) is based on standard reverse capture sandwich enzyme-linked immuno-sorbent assay technology. Dengue Virus u-capture antigen has been pre-coated and blocked in a 96-wellplate (12 x 8 Well Strips). Standards or test samples are added to the wells, incubated and washed. An HRP conjugated detector antibody specific for Human IgM is added, incubated and followed by washing. An enzymatic reaction is produced through the addition of substrate which is catalyzed by HRP generating a blue color product that changes to yellow after adding acidic stop solution. The density of yellow coloration is read by absorbance at 450 nm and is qualitatively proportional to the amount of sample anti-Dengue Virus u-capture IgM captured the in well. | ||||||||||||||||||||||||||||||||||
ELISA Kit Reproducibility |
| ||||||||||||||||||||||||||||||||||
ELISA Kit Component |
| ||||||||||||||||||||||||||||||||||
Reconstitution and Storage | Store as indicated in product manual. | ||||||||||||||||||||||||||||||||||
Sample Type | Serum, Plasma | ||||||||||||||||||||||||||||||||||
Sensitivity | Sensitivity is determined as the probability of the assay indicating a positive score in samples with the specific analyte present: > 98% | ||||||||||||||||||||||||||||||||||
Specificity | Specificity is determined as the probability of the assay indicating a negative score in samples absent of the specific analyte: > 97.5% | ||||||||||||||||||||||||||||||||||
Assay Info | Assay Methodology: Quantitative Reverse Capture Sandwich ELISA |
Alias Symbols | DENV |
---|---|
Protein Name | Dengue Virus u-capture IgM |
Description of Target | Dengue fever, also known as breakbone fever, is an infectious tropical disease caused by the dengue virus and transmitted by mosquitoes. Dengue fever virus (DENV) is a virus of the family Flaviviridae, genus Flavivirus and contains a single-stranded RNA genome with positive polarity. There are four serotypes of the virus, which are referred to as DENV-1, DENV-2, DENV-3 and DENV-4. The geographical distribution is around the equator, particularly Latin America, Central Africa, India, Southeast Asia, Western Pacific and South of the USA. Dengue viruses are transmitted to humans through the bites of infective female yellow fever mosquitoes (Stegomyia aegypti, formerly Aedes aegypti). The mosquitoes generally acquire the virus while feeding on the blood of an infected person. After virus incubation for eight to ten days, an infected mosquito is capable, during probing and blood feeding, of transmitting the virus for the rest of its life. Yellow fever mosquitoes are well adapted to living in close proximity to humans, and to feeding off people rather than other vertebrates. They prefer to lay their eggs in artificial water containers, such as flower vases, uncovered barrels, buckets and discarded tires. The incubation period ranges from 3-14 days, but most often it is 4-7 days. Typically, people infected with dengue virus are asymptomatic or only have symptoms of a common cold. The characteristic symptoms of dengue are sudden-onset fever (up to 40 C) with intense headache (especially behind the eyes), and muscle and joint pain. In combination with a skin rash this symptoms are known as the „dengue triad“. This usually lasts 3-7 days. In some patients the disease proceeds to a critical phase. Dengue Hemorrhagic Fever (DHF) or Dengue Shock Syndrome (DSS) occur in less than 5 % of all cases of dengue. About 1-5 % of severe cases are fatal. In individual epidemics the case-fatality rate may reach up to 15 %. Infection with one serotype is believed to produce lifelong immunity to that serotype but only short term protection against the others. Secondary infection with a different serotype may result in severe clinical manifestations. There is no vaccination available. |